ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Methotrexate Efficacy Versus Cyclosporine in Moderate to Severe Atopic Dermatitis Patients (METHODA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00809172
Recruitment Status : Completed
First Posted : December 17, 2008
Last Update Posted : May 14, 2013
Sponsor:
Information provided by (Responsible Party):
Hospices Civils de Lyon

Brief Summary:

The systemic treatments for moderate to severe atopic dermatitis (AD) are limited to phototherapy and cyclosporine with the risks respectively of either carcinoma, or hypertension or nephropathy.

Methotrexate was effective in 75% of moderate to severe AD patients with good tolerance in an open retrospective study.

We want to confirm our observations: a non inferiority multicenter clinical trial, methotrexate versus cyclosporine, will be conducted in 100 patients for 24 weeks.


Condition or disease Intervention/treatment Phase
Atopic Dermatitis Drug: Ciclosporin Drug: Methotrexate Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicenter Randomised Study of Methotrexate Efficacy Versus Cyclosporine in Moderate to Severe Atopic Dermatitis Patients
Study Start Date : December 2008
Actual Primary Completion Date : October 2011
Actual Study Completion Date : April 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eczema

Arm Intervention/treatment
Active Comparator: 1
Ciclosporin
Drug: Ciclosporin
5 mg/kg/day per os during 8 weeks after the posology will be changed according to clinical response during the next 16 weeks

Experimental: 2
Methotrexate
Drug: Methotrexate
15 mg/week per os in one tablet during 8 weeks after the posology will be changed according to clinical response during the next 16 weeks




Primary Outcome Measures :
  1. proportion of patients with a 50% decrease of scorad ( scorad 50) after 8 weeks of treatment [ Time Frame: 36 months ]

Secondary Outcome Measures :
  1. Decrease of scorad by 50% at week4,12,16,20 and 24 [ Time Frame: at week4,12,16,20 and 24 ]
  2. Decrease of scorad by 75% and 90 % at week 8 and 24 [ Time Frame: at week 8 and 24 ]
  3. quality of life at week 8 and 24 [ Time Frame: at week 8 and 24 ]
  4. Concentration of cytokines CCL17 and CCL18 [ Time Frame: at week 8 and 24 ]
  5. number of adverse events [ Time Frame: 36 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients aged > 18 years old.
  • Both genders eligible for study.
  • Moderate to severe AD.
  • Scorad > 15.
  • Participants must use a contraceptive method during the trial and for 3 months after the end of the trial for female and 5 months for male participants.
  • Participants must be able to understand and sign the Informed Consent, and comply with all aspects of the protocol.
  • Patients must be registered in a social security system or with a health insurance coverage.

Exclusion Criteria:

  • Pregnant or lactating women.
  • Evolutive skin disease.
  • Patients with a clinically significant disease (chronic, recurrent or active).
  • Systemic corticotherapy or immunosuppressive treatment during the previous month, or local corticoid the week before the inclusion.
  • Contra-indication to methotrexate and cyclosporine.
  • Exposure to phototherapy: cumulative dose > 2000 J/cm2.
  • Patients deprived of their civic rights, in custody, or subject to a tutorial, judiciary or administrative decision.
  • Patients under a protection measure.
  • Patients in a critical medical situation.
  • Patients with a personal situation evaluated by the investigator as unable to give optimal participation to the study, or where the study could constitute a risk for the patient.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00809172


Locations
France
Hospices Civils de Lyon
Lyon, France
Sponsors and Collaborators
Hospices Civils de Lyon
Investigators
Principal Investigator: Jean-François Nicolas, Professor Hospices Civils de Lyon

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Hospices Civils de Lyon
ClinicalTrials.gov Identifier: NCT00809172     History of Changes
Other Study ID Numbers: 2007.476
First Posted: December 17, 2008    Key Record Dates
Last Update Posted: May 14, 2013
Last Verified: October 2009

Keywords provided by Hospices Civils de Lyon:
Atopic-dermatitis
scorad
methotrexate
ciclosporin

Additional relevant MeSH terms:
Dermatitis
Dermatitis, Atopic
Eczema
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Methotrexate
Cyclosporine
Cyclosporins
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents
Immunologic Factors
Antirheumatic Agents
Nucleic Acid Synthesis Inhibitors
Antifungal Agents
Anti-Infective Agents